Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.
Institutional and Insider Ownership
67.9% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are owned by institutional investors. 4.7% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Get Acumen Pharmaceuticals alerts:Analyst Ratings
This is a breakdown of recent ratings and price targets for Acumen Pharmaceuticals and Achilles Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acumen Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
| Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
Risk and Volatility
Acumen Pharmaceuticals has a beta of -1.92, suggesting that its share price is 292% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Profitability
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acumen Pharmaceuticals | N/A | -18.16% | -17.72% |
| Achilles Therapeutics | N/A | -26.40% | -23.89% |
Valuation and Earnings
This table compares Acumen Pharmaceuticals and Achilles Therapeutics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acumen Pharmaceuticals | $1.44 million | 161.17 | -$100.61 million | N/A | N/A |
| Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.67 |
Achilles Therapeutics has lower revenue, but higher earnings than Acumen Pharmaceuticals.
About Acumen Pharmaceuticals
(Get Rating)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
About Achilles Therapeutics
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.